Found: 125
Select item for more details and to access through your institution.
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing.
- Published in:
- European Radiology, 2022, v. 32, n. 7, p. 4647, doi. 10.1007/s00330-022-08536-6
- By:
- Publication type:
- Article
Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
- Published in:
- BJU International, 2012, v. 110, n. 5, p. 658, doi. 10.1111/j.1464-410X.2011.10886.x
- By:
- Publication type:
- Article
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
- Published in:
- BJU International, 2005, v. 96, n. 9, p. 1241, doi. 10.1111/j.1464-410X.2005.05821.x
- By:
- Publication type:
- Article
Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
- Published in:
- Japanese Journal of Clinical Oncology, 2022, v. 52, n. 5, p. 441, doi. 10.1093/jjco/hyac015
- By:
- Publication type:
- Article
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
- Published in:
- Japanese Journal of Clinical Oncology, 2021, v. 51, n. 8, p. 1287, doi. 10.1093/jjco/hyab028
- By:
- Publication type:
- Article
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.
- Published in:
- Clinical Genitourinary Cancer, 2023, v. 21, n. 2, p. 230, doi. 10.1016/j.clgc.2023.01.001
- By:
- Publication type:
- Article
Abiraterone has benefits for metastatic castration-resistant prostate cancer.
- Published in:
- British Journal of Hospital Medicine (17508460), 2013, v. 74, n. 1, p. 8, doi. 10.12968/hmed.2013.74.1.8
- By:
- Publication type:
- Article
The molecular underpinnings of prostate cancer: impacts on management and pathology practice.
- Published in:
- Journal of Pathology, 2017, v. 241, n. 2, p. 173, doi. 10.1002/path.4826
- By:
- Publication type:
- Article
The CT flare response of metastatic bone disease in prostate cancer.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
- Published in:
- Cancer & Metastasis Reviews, 2014, v. 33, n. 2/3, p. 555, doi. 10.1007/s10555-013-9473-1
- By:
- Publication type:
- Article
Novel drugs targeting the androgen receptor pathway in prostate cancer.
- Published in:
- Cancer & Metastasis Reviews, 2014, v. 33, n. 2/3, p. 567, doi. 10.1007/s10555-013-9472-2
- By:
- Publication type:
- Article
A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients.
- Published in:
- Cancer Reports, 2024, v. 7, n. 6, p. 1, doi. 10.1002/cnr2.2083
- By:
- Publication type:
- Article
Systematic study of tissue factor expression in solid tumors.
- Published in:
- Cancer Reports, 2023, v. 6, n. 2, p. 1, doi. 10.1002/cnr2.1699
- By:
- Publication type:
- Article
27-hydroxycholesterol and DNA damage repair: implication in prostate cancer.
- Published in:
- Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2023.1251297
- By:
- Publication type:
- Article
Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221100022
- By:
- Publication type:
- Article
LETTER TO EDITORS ABOUT: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer.
- Published in:
- 2016
- By:
- Publication type:
- Letter to the Editor
Molecular pathology and prostate cancer therapeutics: from biology to bedside.
- Published in:
- Journal of Pathology, 2014, v. 232, n. 2, p. 178, doi. 10.1002/path.4272
- By:
- Publication type:
- Article
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
- Published in:
- Journal of Pathology, 2013, v. 229, n. 3, p. 422, doi. 10.1002/path.4140
- By:
- Publication type:
- Article
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 4, p. 1117, doi. 10.1007/s10637-019-00856-7
- By:
- Publication type:
- Article
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 4, p. 1096, doi. 10.1007/s10637-019-00857-6
- By:
- Publication type:
- Article
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 995, doi. 10.1007/s10637-014-0101-x
- By:
- Publication type:
- Article
Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.
- Published in:
- Drugs, 2016, v. 76, n. 4, p. 421, doi. 10.1007/s40265-015-0530-7
- By:
- Publication type:
- Article
PARP Inhibitors Mechanism of Action and Their Potential Role in the Prevention and Treatment of Cancer.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Management of Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer.
- Published in:
- PLoS ONE, 2013, v. 8, n. 6, p. 1, doi. 10.1371/journal.pone.0067148
- By:
- Publication type:
- Article
Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers.
- Published in:
- PLoS ONE, 2012, v. 7, n. 11, p. 1, doi. 10.1371/journal.pone.0047020
- By:
- Publication type:
- Article
Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival.
- Published in:
- PLoS ONE, 2011, v. 6, n. 11, p. 1, doi. 10.1371/journal.pone.0027419
- By:
- Publication type:
- Article
FGF Receptor Inhibitors: Role in Cancer Therapy.
- Published in:
- Current Oncology Reports, 2012, v. 14, n. 2, p. 111, doi. 10.1007/s11912-012-0225-0
- By:
- Publication type:
- Article
Visualizing whole-body treatment response heterogeneity using multi-parametric magnetic resonance imaging.
- Published in:
- Journal of Algorithms & Computational Technology, 2016, v. 10, n. 4, p. 290, doi. 10.1177/1748301816668024
- By:
- Publication type:
- Article
Therapy monitoring of skeletal metastases with whole-body diffusion MRI.
- Published in:
- Journal of Magnetic Resonance Imaging, 2014, v. 39, n. 5, p. 1049, doi. 10.1002/jmri.24548
- By:
- Publication type:
- Article
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
- Published in:
- JNCI Cancer Spectrum, 2020, v. 4, n. 2, p. 1, doi. 10.1093/jncics/pkz093
- By:
- Publication type:
- Article
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.
- Published in:
- JNCI Cancer Spectrum, 2020, v. 4, n. 2, p. 1, doi. 10.1093/jncics/pkaa003
- By:
- Publication type:
- Article
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 1, p. 51, doi. 10.3390/cancers14010051
- By:
- Publication type:
- Article
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
- Published in:
- Cancers, 2021, v. 13, n. 10, p. 2334, doi. 10.3390/cancers13102334
- By:
- Publication type:
- Article
Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study.
- Published in:
- Cancers, 2021, v. 13, n. 6, p. 1284, doi. 10.3390/cancers13061284
- By:
- Publication type:
- Article
Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles.
- Published in:
- Cancers, 2018, v. 10, n. 11, p. 416, doi. 10.3390/cancers10110416
- By:
- Publication type:
- Article
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation.
- Published in:
- Metabolomics, 2020, v. 16, n. 4, p. 1, doi. 10.1007/s11306-020-01676-0
- By:
- Publication type:
- Article
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 760, doi. 10.1007/s10637-012-9869-8
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 1, p. 316, doi. 10.1007/s10637-010-9535-y
- By:
- Publication type:
- Article
Bench to Bedside Development of [ 18 F]Fluoromethyl-(1,2- 2 H 4)choline ([ 18 F]D4-FCH).
- Published in:
- Molecules, 2023, v. 28, n. 24, p. 8018, doi. 10.3390/molecules28248018
- By:
- Publication type:
- Article
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476).
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 3, p. 422, doi. 10.1002/ijc.34018
- By:
- Publication type:
- Article
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 6, p. 993, doi. 10.1002/ijc.33861
- By:
- Publication type:
- Article
Future directions in the evaluation of c-MET-driven malignancies.
- Published in:
- Therapeutic Advances in Medical Oncology, 2011, v. 3, n. 1, p. S51, doi. 10.1177/1758834011423540
- By:
- Publication type:
- Article
c-MET: an exciting new target for anticancer therapy.
- Published in:
- Therapeutic Advances in Medical Oncology, 2011, v. 3, n. 1, p. S3, doi. 10.1177/1758834011423402
- By:
- Publication type:
- Article
Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
- Published in:
- Cancer Imaging, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s40644-023-00644-w
- By:
- Publication type:
- Article
Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
Reappraisal of glucocorticoids in castrate-resistant prostate cancer.
- Published in:
- Asian Journal of Andrology, 2014, v. 16, n. 5, p. 666, doi. 10.4103/1008-682X.133314
- By:
- Publication type:
- Article
Novel Strategies to Test Biological Hypotheses in Early Drug Development for Advanced Prostate Cancer.
- Published in:
- Clinical Chemistry, 2013, v. 59, n. 1, p. 75, doi. 10.1373/clinchem.2012.185157
- By:
- Publication type:
- Article